Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 463 clinical trials
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose (RP2D) (Part 3).

measurable disease
multiple myeloma
  • 0 views
  • 28 May, 2021
  • 76 locations
4SCAR-CD44v6 T Cell Therapy Targeting Cancer

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of 4SCAR-CD44v6 T-cell therapy targeting multiple cancers. The study also aims to learn more about the function of the CD44v6 CAR-T cells and their persistency in the patients.

  • 0 views
  • 25 Jan, 2021
  • 4 locations
Multi-center Trial of Revlimid and Rituximab for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

The study is a two-arm, multi-center trial of Revlimid® and Rituximab, for the frontline treatment of patients with Chronic Lymphocytic Leukemia (CLL) designed and conducted by the CLL Research Consortium (CRC). The purpose of this study is to determine the response rate of the combination of Revlimid® and Rituximab in …

rituximab
lymphoid leukemia
platelet count
revlimid
lenalidomide
  • 42 views
  • 07 Nov, 2020
  • 3 locations
Study of CC-93269 a BCMA x CD3 T Cell Engaging Antibody in Subjects With Relapsed and Refractory Multiple Myeloma

multiple myeloma.

bcma
refractory multiple myeloma
leukemia
bone marrow procedure
measurable disease
  • 174 views
  • 02 Jun, 2021
  • 29 locations
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM

pomalidomide
dexamethasone
daratumumab
proteasome inhibitor
vasectomy
  • 57 views
  • 25 Jan, 2021
  • 47 locations
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma.

pomalidomide
refractory multiple myeloma
dexamethasone
lenalidomide
measurable disease
  • 91 views
  • 14 May, 2021
  • 240 locations
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV)

) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously

maintenance therapy
corticosteroids
dexamethasone
daratumumab
refractory multiple myeloma
  • 21 views
  • 27 May, 2021
  • 163 locations
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 of this study is currently enrolling.

line of therapy
platelet count
refractory multiple myeloma
carfilzomib
dexamethasone
  • 134 views
  • 12 Jun, 2021
  • 46 locations
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

This protocol is a phase III study designed to compare the efficacy and the safety of Isa-KRd induction, transplant, Isa-KRd post ASCT consolidation and Isa-KRd light consolidation vs KRd induction, transplant, KRd post ASCT consolidation and KRd light consolidation After confirmation of eligibility criteria patients will be randomized to one …

  • 0 views
  • 27 Jan, 2021
  • 7 locations
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma the EQUATE Trial

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, …

plasmacytosis
chemotherapy drugs
daratumumab
monoclonal protein
chemotherapy regimen
  • 0 views
  • 03 Jun, 2021
  • 361 locations